STAA Jun 2024 40.000 call
| Previous Close | 7.70 |
| Open | 7.70 |
| Bid | 8.00 |
| Ask | 8.50 |
| Strike | 40.00 |
| Expire Date | 2024-06-21 |
| Day's Range | 7.50 - 8.10 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 497 |
ZacksWall Street's Insights Into Key Metrics Ahead of Staar Surgical (STAA) Q1 Earnings
Beyond analysts' top -and-bottom-line estimates for Staar Surgical (STAA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
Simply Wall St.STAAR Surgical Company's (NASDAQ:STAA) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
STAAR Surgical (NASDAQ:STAA) has had a great run on the share market with its stock up by a significant 64% over the...
Business WireSTAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel
LAKE FOREST, Calif., May 01, 2024--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel. Both will serve on the Company’s executive committee and report to Tom Frinzi, STAAR Surgical’s President and CEO.
